Anlotinib Treatment in Steroid Depenent/Refractory cGVHD

Chronic Graft-versus-host-disease Clinical Trial

Official title:

A Phase 2 Study of Anlotinib in Subjects With Steroid Depenent/Refractory Chronic Graft Versus Host Disease(cGVHD)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04232397
• Other study ID #: SHSYXY-Anlo-cGVHD-2019001
• Status: Terminated
• Phase: Phase 2
• Start date: April 10, 2020
• Est. completion date: March 1, 2021

Study information

• Verified date: March 2021
• Source: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single center, single arm, prospective, phase II clinical study. The main purpose of this study is to evaluate the efficacy and safety of anlotinib in the treatment of steroid dependent/refractory chronic graft-versus-host disease (cGVHD) after allogeneic peripheral blood stem cell transplantation (allo HSCT).

Description:

Anlotinib 8mg qd po for 6months if no progression in 4weeks or reach PR in 3months

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: March 1, 2021
• Est. primary completion date: September 15, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Participants must be diagnosed as hematopoiesis disorders and receiving hematopoietic stem cells transplantation.

2. Steroid dependent or refractory classic chronic GVHD disease defined as modified National Institutes of Health criteria(2014) below at any time post-hematopoietic cell transplant(post-HCT)

1. Dependent disease, defined as, when glucocorticoid (prednisolone doses greater than or equal to(<=) 0.25mg/kg/day or <=0.5mg/kg every other day(prednisolone doses) due to recurrence or progression of cGVHD manifestations, it is considered as steroid-dependent disease if the lowest tapering dose of the second occasion is equal or higher than the lowest tapering dose of the first occasion

2. Refractory disease, defined as, when cGVHD manifestations progress despite the use of a regime containing glucocorticoid (prednisolone at >=1mg/kg/day for at least 1 week) or persist without improvement despite continued treatment with glucocorticoid (prednisolone at >=0.5mg/kg/day or 1mg/kg every other day) for at least 4 weeks.

3. Participants must be receiving baseline systemic glucocorticoid therpy for cGVHD at study entry. The dose of steroids must be stable for 14 days prior to starting anlotinib.

4. At the time of trial enrollment, participants may be receiving other immunosuppressive therapies in addition to glucocorticoids. Immunosuppressant doses must be stable for 14 days prior to starting anlotinib.

5. Neutrophil=1.5×109/L,platelet=50×109/L

6. Karnofsky or Lansky performance status>=60

7. Participants should sign the agreement.

Exclusion Criteria:

1. Known or suspected active acute GVHD.

2. Current treatment with a tyrosine kinase inhibitor, purin analogs or other cancer chemotherapy in the 4weeks prior to starting study drug.

3. Concomitant use of warfarin or other Vitamin K antogonists.

4. Known bleeding disorders or hemophilia.

5. Known history of human immunodeficiency virus or active with hepatitis C. virus or hepatitis B virus.

6. Uncontrolled infections not responsive to antibiotics, antiviral medicines, or antifungal medicine or recent infection requiring systemic treatment .

Related Conditions & MeSH terms

• Chronic Graft-versus-host-disease
• Graft vs Host Disease

Intervention

Drug:
• Anlotinib
anlotinib 8mg qd po

Locations

Country	Name	City	State
China	Hematology Department	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall response rate as the percentage of participants with response.	Overall response rate is defined as the proportion of subjects who achieved complete response CR or partial response PR. Response criteria are based on NIH cGVHD Response assessment.	1year
Secondary	Duration of Response (DOR)	DOR is defined as the duration of time from the date of initial response	1year